ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages bluebird bio, Inc. Investors with Losses over $100K to Secure Counsel Before Important April 13 Deadline in Securities Class Action - BLUENewsfile Corp • 03/23/21
ROSEN, A LEADING LAW FIRM, Encourages bluebird bio, Inc. Investors with Large Losses to Secure Counsel Before Important April 13 Deadline in Securities Class Action - BLUEPRNewsWire • 03/20/21
BLUE INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Has Been Filed Against bluebird bio, Inc.PRNewsWire • 03/18/21
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages bluebird bio, Inc. Investors to Secure Counsel Before Important April 13 Deadline in Securities Class Action – BLUEBusiness Wire • 03/17/21
BLUE SHAREHOLDER FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit That Has Been Filed Against bluebird bio, Inc.GlobeNewsWire • 03/17/21
bluebird bio Presents Long-Term Data for elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD)Business Wire • 03/15/21
BLUE Investor News: Rosen, A Leading and Longstanding Law Firm, Encourages bluebird bio, Inc. Investors with Large Losses to Secure Counsel Before Important Deadline - BLUENewsfile Corp • 03/12/21
bluebird (BLUE) Up on Updated Findings in LentiGlobin's SCD StudyZacks Investment Research • 03/11/21
Bluebird Bio Soars After Gene Therapy Exonerated In Cancer DiagnosisInvestors Business Daily • 03/10/21
Bluebird's stock is up after saying illness reported in clinical trial wasn't likely caused by gene therapyMarket Watch • 03/10/21
DraftKings, H&R Block, Novartis and More Wednesday Afternoon Analyst Calls24/7 Wall Street • 03/10/21
Bluebird Bio Says Lentiviral Vector Not the Cause Of Blood Cancer Reported In Sickle Cell StudyBenzinga • 03/10/21
bluebird bio Provides Updated Findings from Reported Case of Acute Myeloid Leukemia (AML) in LentiGlobin for Sickle Cell Disease (SCD) Gene Therapy ProgramBusiness Wire • 03/10/21
BLUE INVESTOR ALERT: ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages bluebird bio, Inc. Investors with Large Losses to Secure Counsel Before Important Deadline – BLUEGlobeNewsWire • 03/10/21
INVESTOR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action Lawsuit Against bluebird bio, Inc.Business Wire • 03/09/21
BLUE INVESTOR NOTICE: ROSEN, A LEADING LAW FIRM, Encourages bluebird bio, Inc. Investors with Large Losses to Secure Counsel Before Important Deadline - BLUENewsfile Corp • 03/08/21
bluebird bio Stock: Berger Montague Investigates Alleged Securities Fraud Claims Against bluebird bio, Inc. (BLUE); Lead Plaintiff Deadline is April 13, 2021Newsfile Corp • 03/05/21
INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmPRNewsWire • 03/04/21
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages bluebird bio, Inc. Investors with Large Losses to Secure Counsel Before Important Deadline – BLUEGlobeNewsWire • 03/03/21
BLUEBIRD BIO, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against bluebird bio, Inc.GlobeNewsWire • 03/02/21
